(ASPI) ASP Isotopes Common Stock - Ratings and Ratios

ASP Isotopes Inc. (NASDAQ:ASPI) is a development-stage advanced materials company specializing in the production, distribution, marketing, and sale of isotopes for various industries. The company focuses on non-radioactive isotopes such as Molybdenum-100, which is used in medical applications, as well as Carbon-14 and Silicon-28. Additionally, ASP Isotopes is developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium-6, Lithium-7, and Uranium-235. The company was incorporated in 2021 and is headquartered in Washington, D.C.

From a technical standpoint, ASPI is currently trading below its 20-day and 50-day simple moving averages, with the 200-day SMA at 4.30 providing potential support. The stock has shown moderate volatility, with an ATR of 0.59. Resistance levels are at 8.3, 6.4, and 4.9, while the support level is at 3.1. The average 20-day volume is 2,151,122, indicating decent liquidity.

Fundamentally, the company has a market cap of $567.17 million, with a forward P/E of 54.35, reflecting expectations of future earnings growth. However, the current P/E is 0.00, as the company is not yet profitable. The P/B ratio of 9.04 suggests the stock is trading at a premium to its book value. The P/S ratio of 100.65 indicates a high valuation relative to sales, while the RoE of -70.59 highlights significant profitability challenges.